No Prescription |
 |
 | ||
|
IROVEL H AVALIDE |
|
| ||
No Prescription » Prescription Drugs 9 » IROVEL H AVALIDE The combination of irbesartan and hydrochlorothiazide is used to treat high blood pressure. Irbesartan is in a class of medications called angiotensin II antagonists. It works by blocking the action of certain natural chemicals that tighten the blood vessels making blood flow more smoothly. Hydrochlorothiazide is in a class of medications called diuretics ('water pills'). It works by causing the the kidneys to get rid of unneeded water and salt from the body into the urine.The combination of irbesartan and hydrochlorothiazide comes as a tablet to take by mouth. It is usually taken once a day with or without food. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Take irbesartan and hydrochlorothiazide exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.Irbesartan and hydrochlorothiazide controls high blood pressure but does not cure it. It may take 2 to 4 weeks before you feel the full benefit of irbesartan and hydrochlorothiazide. Continue to take irbesartan and hydrochlorothiazide even if you feel well. Do not stop taking irbesartan and hydrochlorothiazide without talking to your doctor. Buy IROVEL H AVALIDE and other Prescription Drugs 9 products online at Medstore. Buy Online at Medstore - Click Here!
About IROVEL H AVALIDE: Product Type: Prescription Drugs 9 IROVEL-H ( AVALIDE GENERIC IRBESARTAN/HYDROCHLOROTHIAZIDE ) IROVEL-H (AVALIDE GENERIC IRBESARTAN/HYDROCHLOROTHIAZIDE) AVALIDE GENERIC IRBESARTAN/HYDROCHLOROTHIAZIDE 150/12.5MG 4 x 50 TABLETS 150/12.5MG 2 x 50 Tablets 150/12.5MG 3 x 30 Tablets 150/12.5MG 2 x 30 Tablets 150/12.5MG 30 Tablets 150/12.5MG 50 Tablet 150/12.5MG 90(3 x 30) Tablets 150/12.5MG 30 Tablets AVALIDE GENERIC IRBESARTAN/HYDROCHLOROTHIAZIDE IROVEL-H
View more Prescription Drugs 9 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
